Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 141 participants.
Also called NCT05145283
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 141 participants
- Registry
-
NCT05145283
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Switzerland
- Registry status
- Completed
Technical summary
Registry record NCT05145283. Randomized; double masking; primary purpose prevention. Start 2022-03-16 (actual); primary completion 2026-01-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation
- Acronym
- PAIR-TAVI
- Condition
- Acute Ischemic Stroke
- Condition
- Acute Renal Injury
- Intervention (Drug)
- Conestat alfa (Ruconest®)
- Intervention (Drug)
- NaCl 0.9%)
- Lead sponsor
- University Hospital, Basel, Switzerland
- Collaborator
- Swiss National Science Foundation
- Collaborator
- Pharming Technologies B.V.
Record details
- Record id
cardio:ct-nct05145283- Content hash
232155fd2da040e326dcb258218c38640159d709229a682479e7fe6e048e2eaf